U.S. marshals have seized tablets of the antidepressant Paxil CR (search) and the diabetes drug Avandamet (search) from several facilities because of manufacturing problems, the FDA says. However, the ...

Federal officials seized two types of drugs Friday from a Knoxville, Tenn., distribution center of GlaxoSmithKline PLC after the Food and Drug Administration found the drug company failed to meet ...

GlaxoSmithKline has returned its antidepressant Paxil CR to the market, nearly four months after federal officials seized the drug from three factories for failing to meet manufacturing standards. The ...

U.S. officials Friday seized batches of GlaxoSmithKline's diabetes drug Avandamet and controlled-release antidepressant Paxil CR because of concerns over manufacturing quality. The U.S. Food and Drug ...

WASHINGTON — The Food and Drug Administration halted distribution Friday of the popular antidepressant Paxil CR and the diabetes drug Avandamet, citing concerns about manufacturing problems. FDA ...

“The language plainly states that GSK may commence marketing and selling of authorized generic Paxil CR after Mylan’s two-year period of exclusivity,” Pisano ruled. “GSK did exactly that. It marketed ...

May 12, 2006 — The US Food and Drug Administration (FDA) and GlaxoSmithKline have warned healthcare professionals regarding the potential increased risk for suicidal behavior associated with use of ...

New Delhi: Lupin Ltd, the country’s Mumbai-based third largest drug maker, said on Friday that it had received tentative approval from the United States Food and Drug Administration (FDA) for its ...

Mylan Inc., the generic-drug maker with an exclusive agreement to sell a copy of GlaxoSmithKline Plc’s Paxil CR, said it won a temporary court order blocking Apotex Inc. from also selling the mood ...

The Food and Drug Administration halted distribution Friday of the popular antidepressant Paxil CR and the diabetes drug Avandamet, citing concerns about manufacturing problems. FDA officials said the ...

Sept. 28, 2005 — The U.S. Food and Drug Administration (FDA) and GlaxoSmithKline have warned healthcare professionals via letter regarding the potential risk of major congenital malformations in ...